BR9814204A - "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral" - Google Patents

"obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"

Info

Publication number
BR9814204A
BR9814204A BR9814204-6A BR9814204A BR9814204A BR 9814204 A BR9814204 A BR 9814204A BR 9814204 A BR9814204 A BR 9814204A BR 9814204 A BR9814204 A BR 9814204A
Authority
BR
Brazil
Prior art keywords
effects associated
pathogenic effects
prevent
protein
host
Prior art date
Application number
BR9814204-6A
Other languages
English (en)
Inventor
Pierre-Francois Serres
Original Assignee
Hippocampe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hippocampe filed Critical Hippocampe
Publication of BR9814204A publication Critical patent/BR9814204A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"OBTENçãO DE VACINAS DESTINADAS A PREVENIR OS EFEITOS PATOGêNICOS ASSOCIADOS A UMA INFECçãO RETROVIRAL"<D>. A invenção refere-se a um método para obter uma vacina contra os efeitos patogênicos associados à infecção de um hospedeiro por um retrovírus, no caso em que as células alvo do retrovírus possuem um receptor de membrana para uma proteína do hospedeiro e onde a infecção viral induz uma resposta imunológica dirigida ao mesmo tempo contra uma proteína de envoltório do vírus e contra uma proteína do hospedeiro. O método consiste em preparar um agente vacinal à base de um polipeptídio compreendendo um fragmento de uma zona imunodominante e conservada da proteína de envoltório do retrovírus, em uma forma modificada tal que o agente vacinal induz uma resposta imunológica dirigida contra a proteína de envoltório e não contra a proteína do hospedeiro.
BR9814204-6A 1997-11-17 1998-11-17 "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral" BR9814204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
PCT/FR1998/002447 WO1999025377A1 (fr) 1997-11-17 1998-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (1)

Publication Number Publication Date
BR9814204A true BR9814204A (pt) 2000-10-03

Family

ID=9513450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814204-6A BR9814204A (pt) 1997-11-17 1998-11-17 "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"

Country Status (19)

Country Link
US (3) US6455265B1 (pt)
EP (1) EP1034000B1 (pt)
JP (1) JP4837823B2 (pt)
KR (1) KR20010032210A (pt)
CN (1) CN1281371A (pt)
AP (1) AP2000001841A0 (pt)
AT (1) ATE353017T1 (pt)
AU (1) AU1243499A (pt)
BR (1) BR9814204A (pt)
CA (1) CA2309676C (pt)
DE (1) DE69837012T2 (pt)
DK (1) DK1034000T3 (pt)
EA (1) EA200000528A1 (pt)
ES (1) ES2281938T3 (pt)
FR (1) FR2771011B1 (pt)
IL (2) IL136163A0 (pt)
OA (1) OA11522A (pt)
PT (1) PT1034000E (pt)
WO (1) WO1999025377A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
DE60336978D1 (de) 2003-04-11 2011-06-16 Pasteur Institut Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
WO2005010033A1 (en) * 2003-07-30 2005-02-03 Mymetics Corporation New soluble and stabilized trimeric form of gp41 polypeptides
ATE435425T1 (de) * 2003-09-11 2009-07-15 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
CA2550264C (en) * 2003-12-18 2011-06-28 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7348136B2 (en) * 2004-02-19 2008-03-25 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA2561376C (en) * 2004-03-30 2016-06-21 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
JP4866848B2 (ja) * 2004-06-30 2012-02-01 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルス（ｆｉｖ）のｅｎｖタンパク質のｖ３領域に由来するペプチドの使用を含むｆｉｖを検出するための方法および装置
US7285278B2 (en) * 2004-06-30 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2005267605B2 (en) * 2004-06-30 2009-03-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1879617A1 (en) * 2005-05-02 2008-01-23 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
US20110195089A1 (en) * 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
AU2010210073B2 (en) 2009-02-06 2016-06-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Splitting gp41
MX2011007703A (es) 2009-02-06 2011-09-28 Mymetics Corp Antigenos gp41 novedosos.
WO2011022725A2 (en) * 2009-08-21 2011-02-24 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
EP2553452B1 (en) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Detection of feline immunodeficiency virus
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
NZ706288A (en) 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用
CN118515733A (zh) * 2023-02-20 2024-08-20 菲鹏生物股份有限公司 Hiv蛋白及其在检测hiv抗体中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
NZ254640A (en) * 1992-07-20 1997-04-24 Univ Duke Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
PT1034000E (pt) 2007-05-31
US6455265B1 (en) 2002-09-24
EP1034000B1 (fr) 2007-01-31
IL136163A (en) 2007-07-04
US7253270B2 (en) 2007-08-07
DE69837012T2 (de) 2007-11-29
FR2771011A1 (fr) 1999-05-21
CA2309676C (fr) 2012-08-07
US20080003229A1 (en) 2008-01-03
AP2000001841A0 (en) 2000-06-30
WO1999025377A1 (fr) 1999-05-27
OA11522A (fr) 2004-02-09
JP4837823B2 (ja) 2011-12-14
EA200000528A1 (ru) 2001-02-26
IL136163A0 (en) 2001-05-20
JP2001524456A (ja) 2001-12-04
CN1281371A (zh) 2001-01-24
EP1034000A1 (fr) 2000-09-13
FR2771011B1 (fr) 2000-01-28
KR20010032210A (ko) 2001-04-16
AU1243499A (en) 1999-06-07
ATE353017T1 (de) 2007-02-15
DE69837012D1 (de) 2007-03-22
US7829683B2 (en) 2010-11-09
DK1034000T3 (da) 2007-06-04
CA2309676A1 (fr) 1999-05-27
ES2281938T3 (es) 2007-10-01
US20040014046A1 (en) 2004-01-22
US20050048478A9 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
BR9814204A (pt) &#34;obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral&#34;
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
DE69426077D1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
BR0014386A (pt) Composição
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
CY1108520T1 (el) Ανασυνδιασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
BR9712592A (pt) Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico
NO976060L (no) Vaksiner mot hepatitt C
DE59913046D1 (de) Influenzavirus-impfstoffzusammensetzung
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
HUP9902710A2 (hu) Rekombináns sertés-poxvírus
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
BR0002602A (pt) Vacina viva atenuada, uso de uma bactéria viva atenuada, e, processo para a preparação de uma vacina
ZA941853B (en) Stimulation of immune response by viral protein
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
BR0210229A (pt) Kit de vacinação, usos de plasmìdeos e uso de vetores virais

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MYMETICS SA (CH)

Free format text: NOME ALTERADO DE: HIPPOCAMPE

B25A Requested transfer of rights approved

Owner name: LOMASTAR TECHNOLOGIES SARL (CH)

Free format text: TRANSFERIDO DE: MYMETICS SA

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.